NASDAQ:RAPT Rapt Therapeutics (RAPT) Stock Price, News & Analysis $10.49 -0.31 (-2.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.52 +0.03 (+0.24%) As of 08/1/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Rapt Therapeutics Stock (NASDAQ:RAPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rapt Therapeutics alerts:Sign Up Key Stats Today's Range$10.10▼$10.9850-Day Range$7.15▼$13.9452-Week Range$5.67▼$26.56Volume31,794 shsAverage Volume98,493 shsMarket Capitalization$173.50 millionP/E RatioN/ADividend YieldN/APrice Target$20.57Consensus RatingModerate Buy Company Overview RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company Read More Rapt Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreRAPT MarketRank™: Rapt Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 180th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingRapt Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageRapt Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Rapt Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rapt Therapeutics are expected to grow in the coming year, from ($2.14) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rapt Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rapt Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRapt Therapeutics has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rapt Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.67% of the float of Rapt Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapt Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Rapt Therapeutics has recently increased by 0.78%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapt Therapeutics does not currently pay a dividend.Dividend GrowthRapt Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.09 Percentage of Shares Shorted5.67% of the float of Rapt Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapt Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Rapt Therapeutics has recently increased by 0.78%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.56 News SentimentRapt Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Rapt Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for RAPT on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.MarketBeat Follows2 people have added Rapt Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rapt Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.36% of the stock of Rapt Therapeutics is held by insiders.Percentage Held by Institutions99.09% of the stock of Rapt Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rapt Therapeutics' insider trading history. Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapt Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPT Stock News HeadlinesRapt Therapeutics (NASDAQ:RAPT) Upgraded to Neutral at JPMorgan Chase & Co.August 1 at 2:16 AM | americanbankingnews.comRAPT Therapeutics Unveils Plans for RPT904 DevelopmentJuly 30 at 11:42 PM | theglobeandmail.comThis Crypto Is Set to Explode in JanuaryFree summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…August 2 at 2:00 AM | Crypto 101 Media (Ad)Rapt Therapeutics upgraded to Neutral from Underweight at JPMorganJuly 30 at 11:42 PM | msn.comJP Morgan Upgrades RAPT Therapeutics (RAPT)July 30 at 11:42 PM | msn.comRapt Therapeutics (NASDAQ:RAPT) Upgraded at Wall Street ZenJuly 28, 2025 | americanbankingnews.comWhat is Lifesci Capital's Estimate for RAPT Q2 Earnings?July 27, 2025 | americanbankingnews.comLifesci Capital Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Strong-BuyJuly 25, 2025 | americanbankingnews.comSee More Headlines RAPT Stock Analysis - Frequently Asked Questions How have RAPT shares performed this year? Rapt Therapeutics' stock was trading at $12.64 at the beginning of 2025. Since then, RAPT shares have decreased by 17.0% and is now trading at $10.49. How were Rapt Therapeutics' earnings last quarter? Rapt Therapeutics (NASDAQ:RAPT) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($2.48) by $1.84. When did Rapt Therapeutics' stock split? Rapt Therapeutics shares reverse split on the morning of Tuesday, June 17th 2025.The 1-8 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Rapt Therapeutics IPO? Rapt Therapeutics (RAPT) raised $39 million in an initial public offering on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO. Who are Rapt Therapeutics' major shareholders? Top institutional investors of Rapt Therapeutics include Medicxi Ventures Management Jersey Ltd (16.89%) and AJU IB Investment Co. Ltd. (0.08%). Insiders that own company stock include Dirk G Brockstedt, William Ho and Wendye Robbins. View institutional ownership trends. How do I buy shares of Rapt Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rapt Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapt Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RAPT CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees80Year Founded2015Price Target and Rating Average Price Target for Rapt Therapeutics$20.57 High Price Target$32.00 Low Price Target$8.00 Potential Upside/Downside+96.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($19.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-81.47% Return on Assets-70.24% Debt Debt-to-Equity RatioN/A Current Ratio21.11 Quick Ratio21.11 Sales & Book Value Annual Sales$1.53 million Price / Sales113.40 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book0.91Miscellaneous Outstanding Shares16,540,000Free Float16,146,000Market Cap$173.50 million OptionableOptionable Beta0.01 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:RAPT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.